Pterostilbene is a dimethylated analog of resveratrol found in blueberries and grapes, with 4x better oral bioavailability (80% vs resveratrol's 20%). Our research shows it addresses resveratrol's biggest weakness — actually getting absorbed. A 2014 RCT found 100mg/day lowered blood pressure by 7.8 mmHg but INCREASED LDL cholesterol by 5-9%, creating a mixed cardiovascular profile. It activates SIRT1 and PPAR-α similarly to resveratrol but at achievable blood levels. The LDL increase is the primary safety concern that distinguishes it from its better-known cousin.
Pterostilbene's two methyl groups (vs resveratrol's hydroxyl groups) make it more lipophilic, dramatically improving absorption and half-life. It activates SIRT1 (longevity pathway), PPAR-α (lipid metabolism), and AMPK (metabolic sensor), while inhibiting NF-κB (inflammation). For blood pressure, it increases NO bioavailability and reduces vascular oxidative stress. The LDL increase mechanism is unclear — it may involve PPAR-α-mediated changes in lipoprotein metabolism. The 4x bioavailability advantage means you can achieve plasma levels with 100mg pterostilbene that would require 500mg+ resveratrol.
No critical interactions identified at standard doses.
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.